TGNA:FRA
Transgene SA
0,67 €
arrow_downward
-0,59%(-0,0040) 1 d.
14. okt., 08:03:02 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: TGNA…
Atvērt
0,67 €
Augsta
0,67 €
Zema
0,67 €
Tirgus kapitalizācija
193,04 milj.
Vid. apjoms
0,00
Apjoms
0,00
Augstākā 52 ned.
1,48 €
Zemākā 52 ned.
0,60 €
Peļņa uz vienu akciju
-0,17 €
Darbinieku skaits
152
Atvērt
0,67 €
Augsta
0,67 €
Zema
0,67 €
Tirgus kapitalizācija
193,04 milj.
Vid. apjoms
0,00
Apjoms
0,00
Augstākā 52 ned.
1,48 €
Zemākā 52 ned.
0,60 €
Peļņa uz vienu akciju
-0,17 €
Darbinieku skaits
152
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Investing News Network
·
pirms 14 minūtēm
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
The Arkansas Democrat-Gazette
·
pirms 21 minūtes
Little Rock based BSR Real Estate Investment Trust shares trading on the New York Stock Exchange
Reuters
·
pirms 2 stundām
Wall St opens lower after hot CPI data fuels rate-hike bets
Profils
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Par “Transgene SA”
Ģenerāldirektors-
Darbinieki152
Dibināšanas datumsdec. 1979
Galvenais birojs-
Sektors-
Tīmekļa vietnetransgene.com